Fig. 1 · Structure

Documents & Downloads

Bleomycin sulfate

Cat. No. A10152 CAS 9041-93-4

DNA/RNA Synthesis inhibitor

Bleomycin sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.

In Stock

Publications for Bleomycin sulfate

3 publications citing this product

  1. Daiheon Lee, .et al. , Drug Deliv Transl Res, 2025, Sep 26 PMID: 41004077
  2. Arina Morozan, .et al. , Sci Rep, 2023, Nov 23;13(1):20577 PMID: 37996447
  3. Mai Kanemaru, .et al. , J Dermatol Sci, 2018, Jan;93(1):41-49 PMID: 30655107

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Blenoxane, reported as a bleomycin A2/B2 mixture, produced an iron-dependent signal consistent with DNA cleavage in a cell-free gold-nanoparticle assay. Fe(II)-supplemented bleomycin retained a dispersed red signal, while bleomycin alone, iron alone and water controls aggregated. Substrate controls supported the cleavage interpretation, although the readout did not directly identify chemical cleavage products. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
UT-SCC-19A 4 nM

Bleomycin sulfate Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Bleomycin sulfate from 4 published references.

Bleomycin sulfate In Vitro Studies

In HeLa cells exposed to iron-supplemented bleomycin sulfate for 24 or 48 h, 50 and 150 µM treatments produced phosphorylated-H2AX foci. At 500 µM, extensive nuclear staining and early apoptotic morphology were observed. These representative images support a DNA-damage response to the reported preparation; late apoptotic cells were lost during staining washes, and the study did not isolate the contribution of added iron. [2]

Iron-dependent DNA-cleavage-associated colorimetric response

Biochemical assay · Double-stranded DNA-functionalized gold nanoparticles in a cell-free assay [1]

Iron(II)-supplemented Blenoxane retained the dispersed red nanoparticle signal, whereas water, iron alone and bleomycin alone showed aggregation-associated color change. Model abasic and protruding-end substrates supported the proposed cleavage-sensitive readout; this remains an indirect assay of DNA cleavage.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Colloidal stability after iron-supplemented Blenoxane treatmentqualitative result Red dispersion retained with Fe(II)·BLM/Blenoxane; water, Fe2+ alone and BLM alone aggregated with a red-to-purple change.[1]
Cleavage-pathway model controlsqualitative result Intact and abasic model substrates aggregated; the protruding-end model retained dispersion.[1]

Literature-Reported Treatment Conditions

Treatment concentration
62 µmol·L−1 bleomycin in Figure 3 and Blenoxane in Figure 6; treatment concentration, not IC50.
Exposure duration
Results describe 10 min at 20–25 °C for visual evaluation following salt addition.
Method
Color observation and UV-visible spectroscopy of DNA-coated gold nanoparticles.
Vehicle
Aqueous phosphate-buffered nanoparticle dispersion; water substitution control.
Co-treatment
Fe(II) supplementation; inactive BLM and Fe2+-only controls.
Reported limits
Exact final-volume and nanoparticle concentration reconstruction is withheld: the general assay methods contain inconsistent volume/unit statements. No assay recipe, potency or kinetic parameter is inferred. Replicate n for Figures 3/6 is not specified in their captions.
Methods and source locations

Compound reported in the paper: Blenoxane (bleomycin A2/B2 mixture)

Evidence for the named Blenoxane mixture under Fe(II) supplementation; no sulfate-specific effect, individual-congener potency or Adooq lot validation.

Materials; colorimetric assay methods; Results and Discussion, Figures 3, 5 and 6

Colloidal stability after iron-supplemented Blenoxane treatment: Visual color and UV-visible comparison; Figure 6 identifies the Blenoxane mixture separately from BLM A5. — Results and Discussion, Figures 3a-b and 6; Materials

Cleavage-pathway model controls: Engineered substrate-control comparison; supports an indirect cleavage interpretation, not direct identification of cleavage products. — Results and Discussion, Figure 5 and Conclusion

DNA-damage-associated nuclear fluorescence in HeLa cells

Cell-based study · Immortalized HeLa cells; untreated controls and iron-supplemented bleomycin exposure [2]

Phosphorylated H2AX foci appeared after treatment, with more foci described at 150 µM than 50 µM and widespread nuclear signal at 500 µM. The high-concentration images represent surviving adherent cells; late apoptotic cells were lost during staining washes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphorylated H2AX staining and nuclear morphologyqualitative result Foci after 50 and 150 µM treatment; more foci described at 150 µM; 500 µM associated with extensive nuclear signal and early apoptotic morphology. Untreated controls lacked the reported repair-foci response.[2]

Literature-Reported Treatment Conditions

Treatment concentration
50, 150 and 500 µM bleomycin (reported treatment concentrations).
Exposure duration
24 or 48 h.
Method
Cell incubation followed by fixation, phospho-H2AX immunofluorescence and DAPI nuclear staining; confocal microscopy.
Vehicle
DMEM treatment medium.
Co-treatment
Bleomycin sulfate solution supplemented with ammonium iron(III) sulfate dodecahydrate before cell exposure; reported bleomycin:iron-salt mass ratio 1:1.1.
Reported limits
No matched iron-only cell control is described in the selected fluorescence methods/results. Effect cannot be assigned to uncomplexed bleomycin sulfate alone. Fluorescence replicate n and quantitative foci counts are not given in Figure 6/corresponding methods; the at-least-three-cell statement concerns Raman acquisition.
Methods and source locations

Compound reported in the paper: Bleomycin sulfate

A DNA-damage response to the reported iron-supplemented sulfate preparation in HeLa cells; no universal cellular potency, repair completion or single-agent specificity claim.

Results, Figure 6 fluorescence paragraph/caption; Methods 4.1, 4.3 and 4.4

Phosphorylated H2AX staining and nuclear morphology: Representative confocal phospho-H2AX/DAPI images at 24 and 48 h; no numerical foci count extracted. — Results, fluorescence paragraph accompanying Figure 6; Figure 6; Methods 4.1, 4.3, 4.4

Bleomycin sulfate In Vivo Studies

In male C57BL/6 mice, subcutaneous minipump delivery of bleomycin reported as Adooq A10152-10 reduced lung compliance and increased resistance and elastance at day 28 versus PBS controls. Lung injury was predominantly inflammatory with minimal histological fibrosis; collagen-positive pixels and affected-area measurements were not significantly different. [3]

An independent bleomycin sulfate study found greater lung fibrosis after eight every-other-week intratracheal doses than after one dose, assessed two weeks after the last exposure. Fibrosis scoring, morphometry and collagen measurements agreed, but reported model-development mortality was higher with repeated exposure (33.3% versus 8.3%). The distinct schedules and surviving cohorts limit direct comparison with other bleomycin injury models. [4]

Systemic bleomycin causes impaired lung mechanics with limited histological fibrosis

Animal study · Male C57BL/6 mice compared with PBS-minipump controls; day 28. [3]

A systemic minipump model impaired lung function, while histology was predominantly inflammatory and collagen-area readouts did not reach significance.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Static compliance, respiratory-system resistance and elastancequalitative result Compliance decreased; resistance and elastance increased versus PBS. Caption: n = 5–10 per group; mean ± SEM.[3]
Lung histology and collagen-positive/affected areasqualitative result Predominantly inflammatory injury with minimal fibrosis. PSR-positive pixel and affected-area differences were labelled ns.[3]

Conditions shared by the study groups

Route
Subcutaneous osmotic minipump.
Frequency
Continuous infusion, 0.5 µL/h for 7 days.
Treatment course
Pump removed day 10; outcomes day 28.
Vehicle
PBS comparator; BLM vehicle not separately specified in pump paragraph.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bleomycin minipump
60 mg/kg nominal bleomycin loading in a 100 µL pump, as reported; actual delivered dose not recalculated.
PBS-loaded osmotic minipump.Lower static compliance and increased resistance/elastance; predominantly inflammatory peripheral injury with minimal fibrosis. Collagen-positive pixels and affected area were nonsignificant.[3]
Bleomycin minipump
Model: Male C57BL/6 mice, 9–10 weeks in Animals; ten weeks in pump protocol.
Reported limits: Do not equate nominal pump loading to a measured systemic exposure; endpoint-specific histology n is not supplied in the caption.
Methods and source locations

Compound reported in the paper: Bleomycin sulfate

Injury-model use of the reported A10152 material; model-specific pulmonary effects with limited histological fibrosis.

Animals; BLM-minipump model; respiratory mechanics and PSR methods; BLM lung Results, Figure 3

Static compliance, respiratory-system resistance and elastance: flexiVent pressure-volume and single-frequency forced-oscillation measurements. — Figure 3a-d and caption; BLM lung Results; respiratory mechanics/PV methods

Lung histology and collagen-positive/affected areas: H&E/MT sections and PSR image analysis; three transverse left-lung sections, excluding airways/large vessels. — Figure 3e-g and caption; BLM lung Results; PSR staining/analysis methods

Bleomycin minipump · Animals; BLM-minipump model; BLM lung Results; Figure 3

Repeated versus single intratracheal bleomycin: fibrosis and mortality

Animal study · Wild-type C57BL/6J mice; lungs assessed 2 weeks after a single or eighth every-other-week dose. [4]

Repeated exposure caused greater fibrosis by three complementary measures, alongside greater reported model-development mortality.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fibrosis score, fibrotic lung area and collagen contentqualitative result All greater after repetitive dosing than single dosing; *P < 0.05 versus single dose. N = 5 per group for score/morphometry; collagen N = 3 untreated and 6 each for single/repetitive. Results presented as means ± SE.[4]
Reported mortality during model-development studiesmortality (%) 8.3% single-dose group versus 33.3% repetitive-dose group; most repetitive-group deaths in first 6 weeks (3 doses).[4]

Conditions shared by the study groups

Route
Intratracheal.
Vehicle
Normal saline.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Single intratracheal dose
0.04 units per mouse in 100 µL.
Repetitive-dose group; untreated collagen comparator. Saline pilot showed no difference from untreated, as reported.Lower fibrosis score, remodeled area and collagen content than repetitive dosing. Model-development mortality: 8.3%.[4]
Repeated intratracheal doses
0.04 units per mouse per administration in 100 µL.
Single-dose group, measured 2 weeks after its dose; untreated collagen comparator.Greater fibrosis score, remodeled area and collagen content than single dosing. Model-development mortality: 33.3%, mostly in the first six weeks.[4]
Single intratracheal dose
Model: Wild-type C57BL/6J mice, ≥8 weeks at study start, 20–30 g.
Frequency: Once.
Treatment course: Endpoints 2 weeks after the dose.
Reported limits: Sex not stated in wild-type mouse methods; mortality denominators are not supplied in the results paragraph.
Repeated intratracheal doses
Model: Wild-type C57BL/6J mice, ≥8 weeks at study start, 20–30 g.
Frequency: Every other week, eight doses.
Treatment course: Endpoints 2 weeks after the eighth dose.
Reported limits: No conversion of activity units to mass. Survivors assessed after substantially different total exposure and age at harvest; mortality may affect surviving cohorts.
Methods and source locations

Compound reported in the paper: Bleomycin sulfate

Model-dependent lung fibrosis and toxicity; not therapeutic efficacy, human IPF equivalence or dose-normalized potency.

Materials and Methods; first two Results subsections, Figure 2

Fibrosis score, fibrotic lung area and collagen content: Blinded 0–4 trichrome fibrosis scoring, calibrated image morphometry and HPLC hydroxyproline-derived collagen. No exact bar heights extracted. — Figure 2A-C/caption; second Results subsection; scoring/morphometry and collagen methods

Reported mortality during model-development studies: Reported survival observation; denominators and statistical comparison not supplied in that paragraph. — First Results subsection, model-development paragraph

Single intratracheal dose · Bleomycin model; first two Results subsections; Figure 2

Repeated intratracheal doses · Bleomycin model; first two Results subsections; Figure 2

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 9041-93-4
Applications DNA/RNA Synthesis inhibitor
Formula C55H84N17O21S3.XHSO4
Molecular Weight 1415.6
Synonyms Blenoxane
SMILES
NC(C[C@H](NC[C@H](N)C(N)=O)C1=NC(N)=C(C)C(C(N[C@H](C(N[C@@H]([C@H]([C@H](C)C(N[C@@H]([C@@H](C)O)C(NCCC2=NC(C3=NC(C(NCCC[S+](C)C)=O)=CS3)=CS2)=O)=O)O)C)=O)C(O[C@@H]4O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]4O[C@@H]5[C@@H](O)[C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O5)C6=CNC=N6)=O)=N1)=O.O=S(O)([O-])=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 93 mg/mL (61.48 mM)
Water 93 mg/mL (61.48 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bleomycin sulfate Research References

  1. [1] Akiyama Y, Kimura K, Komatsu S, et al. A Simple Colorimetric Assay of Bleomycin-Mediated DNA Cleavage Utilizing Double-Stranded DNA-Modified Gold Nanoparticles Chembiochem : a European journal of chemical biology (2023). PMID: 36156837 DOI: 10.1002/cbic.202200451 Source material
  2. [2] Czaja M, Skirlińska-Nosek K, Adamczyk O, et al. Raman Research on Bleomycin-Induced DNA Strand Breaks and Repair Processes in Living Cells International journal of molecular sciences (2022). PMID: 35408885 DOI: 10.3390/ijms23073524 Source material
  3. [3] Morozan A, Joy S, Fujii U, et al. Superiority of systemic bleomycin to intradermal HOCl for the study of interstitial lung disease Scientific reports (2023). PMID: 37996447 DOI: 10.1038/s41598-023-47083-y Source material
  4. [4] Degryse AL, Tanjore H, Xu XC, et al. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis American journal of physiology. Lung cellular and molecular physiology (2010). PMID: 20562227 DOI: 10.1152/ajplung.00026.2010 Source material

Publications

3 publications citing this product

  1. Daiheon Lee, .et al. , Drug Deliv Transl Res, 2025, Sep 26 PMID: 41004077
  2. Arina Morozan, .et al. , Sci Rep, 2023, Nov 23;13(1):20577 PMID: 37996447
  3. Mai Kanemaru, .et al. , J Dermatol Sci, 2018, Jan;93(1):41-49 PMID: 30655107

Added to your cart

View Cart Checkout
Loading...